Prospect of new medicines attracting companies to invest in cat allergy market

NEW YORK - Dec. 4, 2014 - PRLog -- Allergy to cats or cat allergy in humans is an allergic reaction to the allergens that are produced by cats. Of these allergens, the most common ones are the glycoprotein Fel d 1, secreted by the cat's sebaceous glands and Fel d 4, which is expressed in saliva. The cat allergy symptoms are usually characterized by coughing, wheezing, chest tightening, itching, nasal congestion, rash, watering eyes, sneezing, chapped lips, and similar features. Another common form of cat allergy is the reaction to the fur shed by cats.

This report, Cat Allergy Global Clinical Trials Review, H2, 2014, provides data on the cat allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cat Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The data book offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating cat allergy. The trails that have been discontinued are also listed in this report. Apart from that, the commercial landscape of the major universities, institutes, hospitals and companies are also talked about. The countries in Asia and Europe which are contributing most to the cat allergy trials are listed and the scenario in those countries is analyzed in the report.

Present market scenario

In the recent years, there have been some developments in the cat allergy clinical trial segment. There are prospects of new drugs being manufactured which will be able to fight and cure cat allergy effectively. As a consequence, several new companies have shown interest in entering the cat allergy treatment market in an attempt to take advantage of this new opportunity. Circassia Holdings Ltd., an Oxford-based manufacturer of drugs, has decided to enter the market. However, this entry is dependent on the success of the final stage of a drug it is currently experimenting on. If it is successful, the company will be selling its own cat allergy medicines. Biomay AG, Johnson & Johnson, and Benchmark Holdings Plc. are a couple of other companies which are attempting to obtain a share of the market. According to WHO, there are 400 million people all around the globe who suffer from allergies of this type. Thus, the companies are predicted to get a healthy return from their investments.

For further insights, click here